A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer [0.03%]
阿比特龙治疗转移性前列腺癌的单中心真实世界研究
Pongwut Danchaivijitr,Anita Archwamety,Concord Wongkraisri
Pongwut Danchaivijitr
Background: Prostate cancer ranks as the eighth leading cause of cancer-related mortality in Thailand, exhibiting an average annual percent increase in incidence rates of 2.7%. Abiraterone acetate, an active prodrug of ab...
Diagnostic Accuracy of Frozen Section Analysis and Factors Associated with Discordance of Final Histopathology in Mucinous Ovarian Tumor [0.03%]
黏液性卵巢肿瘤冰冻切片诊断准确性及最终病理不符的相关因素分析
Rubi Gupta,Bijal Patel,Pariseema Dave et al.
Rubi Gupta et al.
Aim and objective: This article determines the diagnostic accuracy of frozen section (FS) in case of mucinous ovarian tumor (MOT) and tailoring of intraoperative treatment decision. ...
Active Tuberculosis Risk Associated with Malignancies: A 4-Year Retrospective Study in a Tertiary Care Hospital [0.03%]
基于三级医疗机构的肿瘤合并活动性结核病的回顾性研究
Priyamvada Roy,Kiran Bala,Jaya Biswas et al.
Priyamvada Roy et al.
Background: Tuberculosis (TB) remains an important public health problem worldwide. Risk of acquiring TB in patients diagnosed with cancers remains high and can result due to reactivation or reinfection. We share the expe...
Rahul Krishnatry,Naveen Mummudi,Sarbani Ghosh Laskar et al.
Rahul Krishnatry et al.
Long wait times on starting day of radiotherapy (day 1) can cause dissatisfaction among both patients and healthcare providers. Reducing these wait times will decrease stress and decongest hospital facilities especially in current coronavir...
Primary Intraosseous Synovial Sarcoma: Experience from a Tertiary Cancer Center [0.03%]
原发骨内滑膜肉瘤：三级癌症中心的经验报告
Vishnu Ramanujan,Srikanth Soma,Chandra Kumar Krishnan et al.
Vishnu Ramanujan et al.
Introduction: Primary intraosseous synovial sarcoma (PISS) is a rare cancer of the bone, with few reported cases across literature. Data from our institute reveals seven indigenous cases. This study aims to evaluate these...
Tumor-Induced Osteomalacia: A Case Report of Rare Disease and Literature review [0.03%]
肿瘤诱导性骨软化症一例及文献复习
Shivam Bansal,Vikas Maheshwari,Bishwa Bandhu Niraula et al.
Shivam Bansal et al.
Background: Oncogenic osteomalacia term used for tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of abnormal phosphate metabolism secondary to ectopic endocrine tumors. The diagnosis often becomes difficult ...
Pankaj Vats,Arti Sarin,Hari Mukundan et al.
Pankaj Vats et al.
Introduction: Multiple modalities exist for treating keloids ranging from surgical, medical, chemotherapeutic, and radiation therapy. Different techniques of radiation therapy have been used to treat keloids as an adjuvan...
Mayadevi Poojari,Irappa Madabhavi,Jaydeep Pol et al.
Mayadevi Poojari et al.
Introduction: Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm of antigen-presenting cells within the reticuloendothelial system primarily originating in lymph nodes, but in almost one-third of the patients, ex...
Mutational Profiling by Next-Generation Sequencing in Patients with Metastatic Non-Small Cell Lung Carcinoma: Our Experience [0.03%]
非小细胞肺癌患者次世代定序检测之基因体学分析体验报告
Hitesh Deka,Neelakshi Mahanta,Naba Kumar Kalita et al.
Hitesh Deka et al.
Introduction: According to GLOBOCAN 2020, overall lung cancer is the second most common cancer in both sexes (11.4%) accounting for highest cancer-related mortality (18%). 1 Adenocarcinoma subtype of non-small cell lung c...
Practice Patterns and Incidence of F ebrile Neutr o penia in Patients R eceiving T riplet Drug Chemotherapeutic Regimens in G U T Cancers: Do We Need to Add WBC Growth Factors? (ForGeT GCSF Study) [0.03%]
胃肠肿瘤患者三药联合化疗所致发热性中性粒细胞减少的发病情况和模式：需不需要使用WBC生长因子？(ForGET GCSF研究)
Kapu Venkatesh,Anant Ramaswamy,Noorzia Sultana et al.
Kapu Venkatesh et al.
Background and objectives: There are limited data on the requirement and duration of white blood cell (WBC) growth factor (GF) administration in patients receiving biweekly docetaxel, oxaliplatin, leucovorin, 5 Fluorourac...